STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough lung cancer
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sapanisertib and osimertinib, for people with advanced non-small cell lung cancer. The cancer must have a specific genetic change (EGFR mutation) and has gotten worse after treatment with a standard targeted drug. …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 20:26 UTC
-
Major trial tests daily pill to stop lung Cancer's return
Disease control OngoingThis large study is testing whether taking a daily pill called erlotinib for two years after lung cancer surgery helps patients live longer. It compares the pill to just regular check-ups (observation) in patients whose cancer has a specific genetic change (EGFR mutation). The go…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug boosts standard treatment in fight against advanced lung cancer
Disease control OngoingThis study is testing if adding an experimental drug called veliparib to standard chemotherapy and radiation works better for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the combination helps patients live longer witho…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial tests immune therapy to stop lung Cancer's comeback
Disease control OngoingThis large Phase 3 trial tested whether giving the immunotherapy drug nivolumab after surgery and chemotherapy could help prevent lung cancer from returning. It involved 903 patients with stage IB-IIIA non-small cell lung cancer who had their tumors surgically removed. The study …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test new drug duo to starve and stop advanced cancers
Disease control OngoingThis study is testing whether taking two oral drugs, cediranib and olaparib, together can help control advanced cancers that have spread or cannot be surgically removed. It is for adults with specific types of advanced lung, breast, or pancreatic cancer who have already tried at …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Massive study maps lung cancer genes to personalize future care
Knowledge-focused OngoingThis large study aims to understand the genetic makeup of lung cancer tumors after they have been surgically removed. It will test tumor samples from 8,300 patients with early-stage non-small cell lung cancer to identify specific genetic changes. The goal is to use this genetic i…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC